📡 Signal Thesis
Synthetic biology is showing pronounced signal acceleration, with 30-day mentions (141) more than doubling the prior 90-day baseline (63), reinforced by positive article sentiment and Twist Bioscience's +37% quarterly move signaling renewed confidence in DNA synthesis infrastructure. The bifurcation between platform/tools leaders (TWST, BEAM) and legacy gene therapy names (SGMO -50%) suggests capital and attention are consolidating around scalable foundries and base-editing modalities rather than first-generation cell therapy approaches. Expect the next 6-12
📊 Signal Evidence
141
Signals last 30 days
63
Signals last 90 days
6.7x
Current vs 90-day avg rate
Positive (+0.19)
Article sentiment
🏢 Top Companies & Domain Index
👁️
Showcase mode.
Company pages marked Premium will require a paid subscription when the platform launches. Full intelligence is visible now.
FSI Synthetic Biology Index
▼ 0.1%
Average 90-day return across top 4 tracked companies
TWST +37.3% · SGMO -50.0% · NTLA -1.5% · BEAM +13.9%
| Ticker | Price | 30-Day Return | 90-Day Return |
|---|---|---|---|
| TWST#1 | $66.87 | +17.9% | +37.3% |
| SGMO#2 | $0.22 | +69.2% | -50.0% |
| NTLA#3 Premium | $14.07 | +13.1% | -1.5% |
| BEAM#4 Premium | $32.93 | +12.1% | +13.9% |
Companies identified by FSI signal pipeline as operating in this domain. Not a recommendation to buy or sell.
🔬 Technology Intelligence Brief
Fundamental Research
Applied Research
Early Commercial
Scaling
Mature
Recent Breakthroughs
AI-designed proteins and generative biology models (RFdiffusion, ESM3, Evo) have dramatically compressed design cycles, enabling functional enzymes and binders to be created in silico with unprecedented hit rates. Concurrent advances in high-throughput DNA synthesis economics at Twist and in vivo base/prime editing clinical readouts (notably Beam and Verve) are converting platform promises into validated therapeutic and industrial outputs. Cell-free systems and continuous bioprocessing are also reducing scale-up risk for non-pharma applications like materials and specialty chemicals.
12–24 Month Milestones to Watch
Watch for pivotal clinical data from in vivo gene editing programs (NTLA-2002, BEAM-302, Verve VERVE-102) that could establish regulatory precedent for one-shot genetic medicines in 2025-2026. On the industrial side, monitor unit economics disclosures from fermentation-based players post-Amyris/Ginkgo restructuring, plus FDA guidance on AI-designed biologics and any USDA/EPA frameworks for engineered microbes in agriculture.
🚀 Accelerators
A clean regulatory approval for an in vivo edited therapy combined with foundation-model-designed drugs entering Phase 1 would catalyze capital re-rating across the sector. Defense and biosecurity funding tailwinds (BIOSECURE Act, DoD biomanufacturing) could also pull forward domestic scale-up timelines by 2-3 years.
⚠️ What Could Stall It
A high-profile safety event in gene editing trials (off-target effects, immunogenicity) or repeated industrial-scale fermentation failures would reinforce the post-Zymergen skepticism and choke off growth capital. Tighter biosecurity restrictions on DNA synthesis and AI-bio dual-use models could also slow iteration speed.
Not investment advice. This scorecard is general signal intelligence derived from publicly available data. It does not constitute personalised investment advice or a recommendation to buy, sell, or hold any security. Past signal momentum does not guarantee future price performance. Capital at risk.